Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Kenneth P JohnsonMaryland Center for MS, Baltimore, Maryland, USAAbstract: An understanding of the risks, benefits, and relative value of glatiramer acetate (GA) in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: REGARD (REbif vs Glatiramer Acetate in Rela...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/risks-vs-benefits-of-glatiramer-acetate-a-changing-perspective-as-new--a4228 |